Shares of Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) took a hit Tuesday after their promising new products failed clinical trials. Biogen's experimental drug aimed at treating multiple sclerosis failed a mid-staged trial, prompted investors to sell shares. Biogen stock is a holding of Jim Cramer's Action Alerts PLUS charitable trust. Our Jim Cramer says the so-called 'novel' therapy turned out to be yet another 'disaster in Biogen's history of overpromising and under- delivering.' And, Alexion Pharmaceuticals also said that a medication it was developing aimed to treat muscle weakness, produced lackluster results. Alexion said in a statement the study also missed its 'primary endpoint' and that cases of successful responses to the drug 'missed statistical significance.'
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.